GlassScriptPhysician profile
Paige E Buresh
NPI 1124750559
$1,896.62
in general payments reported to CMS, 2019-2025
17 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $1,050 · 2024: $390 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $721.41 | 2023-2025 | |
| Tris Pharma INC | $189.35 | 2022-2023 | Dyanavel Xr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.27 | 2024-2025 | Lifevest |
| Corium, LLC | $136.20 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $136.00 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.02 | 2022-2023 | |
| Axsome Therapeutics, INC. | $82.33 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $70.81 | 2023 | Quviviq |
| Lundbeck LLC | $62.96 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $49.23 | 2023-2025 | Invega Sustenna, Spravato |
| Bausch Health US, LLC | $40.81 | 2023 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $38.37 | 2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $27.56 | 2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $21.63 | 2023 | Jornay Pm |
| Neos Therapeutics, LP | $16.25 | 2024 | Adzenys Xr-Odt |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $14.96 | 2023 | Qelbree |
| Harmony Biosciences LLC | $6.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Buresh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.